Hepatorenal syndrome acute kidney injury (HRS-AKI) affects 9,000 to 35,000 patients in the U.S. and is the most common cause of hospitalization and mortality in patients with cirrhosis. HRS-AKI is reversible if treated immediately but can lead to irreversible kidney damage and death with delayed diagnosis and treatment.
However, diagnosing and treating HRS-AKI can be challenging because it shares many symptoms with other kidney disorders.
That’s why AGA developed comprehensive education featuring four podcasts from expert faculty and four articles in Clinical Gastroenterology and Hepatology (CGH) to help you improve your knowledge and skills in HRS-AKI management. This education will help you:
- Distinguish HRS-AKI from other kidney disorders with overlapping symptoms.
- Evaluate the use of current and emerging pharmacological and non-pharmacological therapies of HRS-AKI.
- Understand the role of liver and kidney transplant in the treatment of HRS-AKI and the organ waitlist prioritization criteria.
AGA’s podcast and journal series makes learning easy for you. You can listen to the podcasts and read the articles at your own pace and convenience. By completing this education, you can earn up to four CME credits: two for viewing all four podcasts and an additional two for reading the four journal articles.
This series is supported by an independent educational grant from Mallinckrodt.
